These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

134 related articles for article (PubMed ID: 18327217)

  • 1. BiDil flops.
    Huggett B
    Nat Biotechnol; 2008 Mar; 26(3):252. PubMed ID: 18327217
    [No Abstract]   [Full Text] [Related]  

  • 2. Grassroots marketing in a global era: more lessons from BiDil.
    Rusert BM; Royal CD
    J Law Med Ethics; 2011; 39(1):79-90. PubMed ID: 21314797
    [No Abstract]   [Full Text] [Related]  

  • 3. Drug targeting: is race enough?
    Wadman M
    Nature; 2005 Jun; 435(7045):1008-9. PubMed ID: 15973367
    [No Abstract]   [Full Text] [Related]  

  • 4. BiDil (isosorbide dinitrate and hydralazine): a new fixed-dose combination of two older medications for the treatment of heart failure in black patients.
    Carmody MS; Anderson JR
    Cardiol Rev; 2007; 15(1):46-53. PubMed ID: 17172884
    [TBL] [Abstract][Full Text] [Related]  

  • 5. BiDil for heart failure in black patients.
    Kahn JD
    Ann Intern Med; 2007 Aug; 147(3):215; author reply 215-6. PubMed ID: 17679713
    [No Abstract]   [Full Text] [Related]  

  • 6. BiDil for heart failure in black patients.
    Bibbins-Domingo K; Fernandez A
    Ann Intern Med; 2007 Aug; 147(3):214-5; author reply 215-6. PubMed ID: 17679712
    [No Abstract]   [Full Text] [Related]  

  • 7. Race, pharmacogenomics, and marketing: putting BiDil in context.
    Kahn J
    Am J Bioeth; 2006; 6(5):W1-5. PubMed ID: 16997802
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Race-based therapeutics.
    Bloche MG
    N Engl J Med; 2004 Nov; 351(20):2035-7. PubMed ID: 15533852
    [No Abstract]   [Full Text] [Related]  

  • 9. Fixed-dose isosorbide dinitrate-hydralazine: race-based cardiovascular medicine benefit or mirage?
    Ferdinand KC
    J Law Med Ethics; 2008; 36(3):458-63. PubMed ID: 18840236
    [TBL] [Abstract][Full Text] [Related]  

  • 10. New heart-failure therapy takes race into account.
    Thompson CA
    Am J Health Syst Pharm; 2005 Sep; 62(17):1745, 1748. PubMed ID: 16120728
    [No Abstract]   [Full Text] [Related]  

  • 11. Maker of heart drug intended for blacks bases price on patients' wealth.
    Saul S
    N Y Times Web; 2005 Jul; ():C3. PubMed ID: 16060015
    [No Abstract]   [Full Text] [Related]  

  • 12. BiDil for heart failure in black patients: The U.S. Food and Drug Administration perspective.
    Temple R; Stockbridge NL
    Ann Intern Med; 2007 Jan; 146(1):57-62. PubMed ID: 17200223
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Studying treatment of heart failure in blacks.
    Brandt D
    Am J Nurs; 2005 Feb; 105(2):20. PubMed ID: 15674043
    [No Abstract]   [Full Text] [Related]  

  • 14. Prescribing BiDil: is it black and white?
    Haga SB; Ginsburg GS
    J Am Coll Cardiol; 2006 Jul; 48(1):12-4. PubMed ID: 16814642
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Fixed-Dose Versus Off-Label Combination of Isosorbide Dinitrate Plus Hydralazine Hydrochloride: Retrospective Propensity-Matched Analysis in Black Medicare Patients with Heart Failure.
    Ofili E; Anand I; Williams RA; Akinboboye O; Xu L; Puckrein G
    Adv Ther; 2017 Aug; 34(8):1976-1988. PubMed ID: 28707284
    [TBL] [Abstract][Full Text] [Related]  

  • 16. U.S. to review drug intended for one race.
    Saul S
    N Y Times Web; 2005 Jun; ():A1, A15. PubMed ID: 15966118
    [No Abstract]   [Full Text] [Related]  

  • 17. Bidil: recontextualizing the race debate.
    Séguin B; Hardy B; Singer PA; Daar AS
    Pharmacogenomics J; 2008 Jun; 8(3):169-73. PubMed ID: 18195727
    [No Abstract]   [Full Text] [Related]  

  • 18. Illuminating BiDil.
    Nat Biotechnol; 2005 Aug; 23(8):903. PubMed ID: 16082345
    [No Abstract]   [Full Text] [Related]  

  • 19. FDA approves heart drug for black patients.
    Meadows M
    FDA Consum; 2005; 39(5):8-9. PubMed ID: 16419285
    [TBL] [Abstract][Full Text] [Related]  

  • 20. BiDil: assessing a race-based pharmaceutical.
    Brody H; Hunt LM
    Ann Fam Med; 2006; 4(6):556-60. PubMed ID: 17148635
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.